Facts about the cost of patented drugs in Canada
The cost of patented drugs is often cited to justify the regulation of pharmaceutical markets and to restrict public and private insurance coverage of new medicines. What are the facts about the cost of patented drugs in Canada? Read More »
Adverse drug reactions in Canada: facts v. urban myths
Alarmist claims about fatal drug reactions: are they supported by the facts? Read More »
Comparing access to new medicines by therapeutic class in public and private sector plans in Canada.
How good is your drug insurance coverage for the medicines that are most important to you? Read More »
Private insurance spending on drugs, dental and vision care in Canada, 1990 to 2010.
The private insurance industry doesn't want to cover new drugs, says costs are unsustainable and demands regulation. But the facts show spending by private insurers on new drugs is growing slower than their spending on dental services and vision care. Read More »
Potential costs from therapeutic substitution of proton pump inhibitor (PPI) drugs in Quebec
Lessons for Quebec from BC's experience with therapeutic substitution for PPI drugs? Read More »
Les coûts potentiels découlant de la substitution thérapeutique des médicaments de la classe des inhibiteurs de la pompe à protons (IPP) au Québec
Leçons pour le Québec de l'expérience de la Colombie-Britannique avec la substitution thérapeutique pour les médicaments IPP? Read More »
Does the increase in safety warnings from regulators actually mean that more dangerous drugs are being approved?
No link between faster drug approvals, regulatory safety warnings and drug withdrawals in Canada and the USA. Read More »
Medical devices and healthcare costs in Canada and 65 other countries 2006-2011
What is the impact of medical device spending on total healthcare costs in Canada? How does Canada compare to other countries? Read More »
How good is your drug insurance?
How good is your drug insurance coverage? It depends on where you live and whether you are publicly or privately insured... Read More »
Drugs and the public cost of healthcare in Canada
What is the impact of drugs on the public cost of healthcare? New research examines the facts... Read More »
Societal economic costs of generic OxyContin abuse could exceed price savings by $352 to $415 million annually
Ontario’s Minister of Health requests ban on generic OxyContin saying the costs to society far outweigh the savings. What does the evidence say?... Read More »
Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in British Columbia
In 2003, BC PharmaCare required patients to make a medically unnecessary switch from the drug prescribed by their doctor to one approved by the government, in order to save money. Did it work? Read More »